A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma	Recruiting	Phase 2	2026-07-29		NCT06541847

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Healx Limited	1

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	United States	144
Children's Hospital Colorado	Aurora	United States	312
Children's Hospital Los Angeles	Los Angeles	United States	226
Children's Hospital of Philadelphia	Philadelphia	United States	434
Children's National Hospital	Washington D.C.	United States	100
Cincinnati Children's Hospital Medical Center	Cincinnati	United States	405
Indiana University	Indianapolis	United States	160
Johns Hopkins Hospital	Baltimore	United States	135
New York University Langone Health	New York	United States	18
Stanford University	Palo Alto	United States	161
University of Alabama at Birmingham	Birmingham	United States	247
University of Chicago	Chicago	United States	312
University of Texas Southwestern Medical Center	Dallas	United States	249
Washington University School of Medicine	St Louis	United States	895